Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Normal tissue effects: reporting and analysis.

Soren M Bentzen1, Wolfgang Dörr, Mitchell S Anscher

  • 1Gray Cancer Institute, Mount Vernon Hospital, Northwood, UK. bentzen@gci.ac.uk

Seminars in Radiation Oncology
|August 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergence in poxvirus-encoded E3-like proteins can dictate poxvirus activation of cellular necroptosis.

Journal of virology·2026
Same author

In Reply to DeLaney.

International journal of radiation oncology, biology, physics·2026
Same author

Increased frequency of remote and off-site work impacts incident learning workflows in radiation oncology.

Technical innovations & patient support in radiation oncology·2026
Same author

Navigating Variability in Prostate RT Planning: Real-Time Insights for Human-Centered CDS Design.

AMIA ... Annual Symposium proceedings. AMIA Symposium·2026
Same author

Reirradiation Collaborative Group (ReCOG) consensus on standards for dose evaluation and reporting in patients with multiple courses of radiation therapy: an AAPM/ACRO/ASTRO/CARO/COMP/CADRA/CPQR/ESTRO/NRG-endorsed consensus statement.

The Lancet. Oncology·2026
Same author

Implementation of a Multihospital Electronic Medical Record-Based Insulin Order Set to Reduce Hypoglycemic Events.

AACE endocrinology and diabetes·2025
Same journal

Integrative Medicine for Breast Cancer Survivors.

Seminars in radiation oncology·2026
Same journal

Integrative Oncology Approaches for Gastrointestinal Symptoms and Risk Reduction in Patients With Digestive Tract Cancers.

Seminars in radiation oncology·2026
Same journal

Integrative Oncology and Radiation Therapy: An Essential Evolution.

Seminars in radiation oncology·2026
Same journal

Clinical Trials of Integrative Oncology Interventions for Radiation Therapy: Emerging Evidence and Opportunities.

Seminars in radiation oncology·2026
Same journal

Nonpharmacologic Approaches for Pain Management in Patients With Cancer Treated With Radiation Therapy.

Seminars in radiation oncology·2026
Same journal

Integrative Therapies for Radiation-Related Toxicities in Hematological Malignancies.

Seminars in radiation oncology·2026
See all related articles

Quantifying normal tissue effects from cancer therapies is crucial for advancing patient care. Standardized reporting guidelines are needed to ensure comparable and reliable data on treatment outcomes.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Clinical Trials

Background:

  • Cancer therapies often cause normal tissue effects, impacting patient outcomes.
  • Optimizing cancer treatments requires reliable quantification of these adverse effects.
  • Advancing cancer care necessitates robust methods for assessing normal tissue toxicity.

Purpose of the Study:

  • To review issues in reporting and analyzing clinical normal tissue effect data.
  • To discuss desirable properties of toxicity reporting and grading criteria.
  • To highlight statistical considerations and study design for normal tissue endpoints.

Main Methods:

  • Literature review of normal tissue effect data analysis in cancer therapy.
  • Distinction between explorative and pragmatic study designs.

Related Experiment Videos

  • Discussion of biological, clinical, and statistical perspectives on toxicity assessment.

    • Main Results:

    • Explorative vs. pragmatic study distinctions are proposed.
    • Validation of toxicity criteria and statistical analysis of time-evolution data are discussed.
    • Surrogate markers for late effects and study designs with normal tissue endpoints are considered.

    Conclusions:

    • Consensus on guidelines for reporting normal tissue effects is essential.
    • Improved comparability of treatment outcome reports is a key goal.
    • Standardized reporting will enhance the reliability of cancer therapy evaluations.